CSL Limited (CSLLY) Q2 2026 Earnings Call Transcript
CSL Limited (CSLLY) Q2 2026 Earnings Call Transcript
CSLLY or TECH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now?
CSL Limited: Upside Potential Is Strong From These Levels But I Remain Cautious
CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. CSL's vaccine business volatility and slow margin recovery, especially at CSL Behring, have weighed on share price and profitability since COVID-19. Management plans to demerge CSL Seqirus by FY 2026, aiming to address earnings volatility, and refocus on core plasma and kidney disease therapies.
CSL Limited (CSLLY) Analyst/Investor Day Prepared Remarks Transcript
CSL Limited (OTCQX:CSLLY) Analyst/Investor Day November 4, 2025 6:00 PM EST Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Paul McKenzie - MD, CEO & Executive Director Dave Ross - Senior VP & GM of Seqirus Presentation Fiona Mead Company Secretary & Head of Corporate Governance Hello. I'm Fiona Mead, CSL's Company Secretary.
CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q4 2025 Earnings Conference Call August 18, 2025 8:00 PM ET Company Participants Andy Schmeltz - Executive Vice President of CSL Behring Chris Cooper - Head of Investor Relations Herve Gisserot - Senior VP & GM of Vifor Joy Carolyn Linton - Chief Financial Officer Paul F. McKenzie - MD, CEO & Executive Director Conference Call Participants Andrew Goodsall - MST Financial Services Pty Limited, Research Division Andrew Paine - CLSA Limited, Research Division Craig Wong-Pan - RBC Capital Markets, Research Division David A.
CSL Limited (CSLLY) Q2 2025 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q2 2025 Results Earnings Conference Call February 10, 2025 7:00 PM ET Company Participants Chris Cooper - Vice President and Head of Investor Relations Paul McKenzie - Chief Executive Officer and Managing Director John Levy - Interim Chief Financial Officer Joy Linton - Interim Executive Vice President, CSL Behring Dave Ross - Senior Vice President and General Manager, CSL Seqirus Hervé Gisserot - Senior Vice President and General Manager, CSL Vifor Conference Call Participants Lyanne Harrison - Bank of America Davinthra Thillainathan - Goldman Sachs David Stanton - Jefferies David Low - J.P. Morgan Andrew Goodsall - MST Marquee Sacha Krien - Evans & Partners Saul Hadassin - Barrenjoey Craig Wong-Pan - RBC Capital Markets Steve Wheen - Jarden Andrew Paine - CLSA Laura Sutcliffe - UBS Mathieu Chevrier - Citigroup Shane Storey - Wilsons Advisory and Stockbroking Limited Thomas Wakim - Bell Potter Securities David Bailey - Macquarie Securities Shane Ponraj - Morningstar Operator Thank you for standing by and welcome to the CSL Limited Half Year Financial Results.
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients.
CSL Limited: Good Results Overshadowed By Below-Expectations Guidance
CSLLY's FY 2024 results were good thanks to the outperformance of the Behring segment; the company's net profit in constant currency terms grew +15% YoY to $2.91 billion, which was in line with expectations. But CSL Limited's FY 2025 earnings guidance was a miss, and this is likely attributable to the expected underperformance of the Seqirus and Vifor segments. My rating for CSL Limited stays as a Hold, as the company's strong FY 2024 earnings growth was obscured by its disappointing FY 2025 bottom line guidance.
CSL Limited (CSLLY) Q4 2024 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q4 2024 Results Conference Call August 12, 2024 9:00 PM ET Company Participants Joy Linton - CFO Chris Cooper - Head, IR Paul McKenzie - MD, CEO & Executive Director Ken Lim - Chief Strategy Officer Conference Call Participants Lyanne Harrison - Bank of America Saul Hadassin - Barrenjoey Gretel Janu - Evans & Partners Steve Wheen - Jarden Andrew Goodsall - MST Marquee David Low - JPMorgan Craig Wong-Pan - RBC David Stanton - Jefferies Laura Sutcliffe - UBS Mathieu Chevrier - Citi David Bailey - Macquarie Joy Linton Good morning, everyone, and welcome to CSL's Financial Year 2024 Results Presentation. I'm Joy Linton, CSL's Chief Financial Officer.
Australia's CSL falls on weaker-than-expected annual profit forecast
Shares of CSL Ltd fell more than 3% on Tuesday after the Australian biotech firm forecast an annual profit that was higher than a year earlier but below market consensus.
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
